Telefonni Seznam

Main Menu

  • Home
  • Phonebook
  • Telephone directory
  • Telephone book
  • Phone contact
  • Telecommunications network

Telefonni Seznam

Header Banner

Telefonni Seznam

  • Home
  • Phonebook
  • Telephone directory
  • Telephone book
  • Phone contact
  • Telecommunications network
Phone contact
Home›Phone contact›Reata Pharmaceuticals, Inc. Sued for Securities Law Violations; Investors should contact Block & Leviton for more information

Reata Pharmaceuticals, Inc. Sued for Securities Law Violations; Investors should contact Block & Leviton for more information

By Catherine H. Perez
December 21, 2021
0
0


BOSTON, MA / ACCESSWIRE / December 21, 2021 / Block & Leviton announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (NASDAQ: RETA) for potential violations of securities law. Investors who have bought stocks and lost money are encouraged to contact the firm to learn more about how they might recoup those losses. For more details, visit https://www.blockleviton.com/cases/reta.

What is all this?

On November 9, 2021, Reata announced that its CARDINAL phase 3 study of bardoxolone in patients with chronic kidney disease caused by Alport syndrome “had met its primary and secondary endpoints by the end of the l ‘year 2 “and that”[b]building on these positive results and following a recently completed pre-NDA meeting with the [FDA], we plan to proceed with the submission of an NDA… in the first quarter of 2021. ”

However, FDA briefing documents released on December 6, 2021 indicate that the FDA “did not agree with the proposed approach” to submit an NDA for bardoxolone under the fast-track approval path. based mainly on data from year 1 on the eGFR of phase 3 of CARDINAL. At the pre-NDA meeting, the FDA had “voice[ed] concerns about the interpretability of the eGFR results… as well as the amount of missing data in the bardoxolone arm and the lack of clarity on how patients with missing data were treated in key analyzes…. “

The company’s shares plunged nearly 40% on December 6, 2021 after the disclosure of the backgrounders.

Then, on Wednesday, December 8, 2021, after the market closed, Reata announced that an FDA advisory committee had voted “no” on whether data submitted by Reata shows bardoxolone is slowing the progression of drug use. chronic kidney disease and whether its benefits outweigh its risks. Reata stock fell 42.8% on the pre-market the next day, December 9, 2021.

Who is eligible?

Anyone who purchased Reata Pharmaceuticals, Inc. shares between November 9, 2020 and December 8, 2021 is potentially eligible whether or not they have sold their investment. Investors should contact Block & Leviton to find out more.

What should you do next?

The deadline to apply for appointment as a lead applicant is February 18, 2022. A group has not yet been certified, and until certification takes place, you are not represented by legal counsel. If you choose not to take any action, you can remain an absent member of the group.

If you have lost money on your investment, you should contact Block & Leviton to find out more through our case website, by email at [email protected], or by phone at (617) 398-5600.

Why contact Block & Leviton?

Many law firms have published press releases on this subject; most of these companies do not actually litigate class actions in securities. Block & Leviton is a real business law firm. We are committed to securing large collections on behalf of defrauded investors through active litigation in federal courts across the country. Many of the country’s leading institutional investors hire us to represent their interests. You can know more about us on our website, www.blockleviton.com, or call (617) 398-5600 or email [email protected] with any questions.

This notice may constitute a lawyer advertisement.

CONTACT:
BLOC & LEVITON LLP
260 Franklin Street, Suite 1860
Boston, MA 02110
Telephone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com

THE SOURCE: Block & Leviton LLP

See the source version on accesswire.com:
https://www.accesswire.com/678866/Reata-Pharmaceuticals-Inc-Sued-for-Securities-Law-Violations-Investors-Should-Contact-Block-Leviton-for-More-Information


Related posts:

  1. Alert (RVNC): Have you lost money on your Revance Therapeutics investment? Contact Johnson Fistel about the investigation
  2. Global Consumer Grade Contact Image Sensors Market Product Type, Industry Segmentation, and Technology Innovations 2021 to 2026
  3. Contact Lens Market Expected To Grow At A Strong Rate 2021-2028 | Novartis International AG, Menicon Group, The Cooper Companies, Inc.
  4. Pateros publishes contact sports guidelines – Manila Bulletin

Categories

  • Phone contact
  • Phonebook
  • Telecommunications network
  • Telephone book
  • Telephone directory

Recent Posts

  • (DGX) News: Contact Leading La
  • Everything you need to know about emergency funds
  • Ofelia A. Villanueva’s new book ‘Return to the Earth’ is an exciting quest for answers to a man’s biggest questions in life
  • Aarogya Setu’s journey from a quick fix for contact tracing to ‘the nation’s health app’
  • Nigerian Drivers of Digital Prosperity – TechEconomy.ng

Archives

  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • December 2019
  • November 2019
  • October 2019
  • July 2019
  • April 2019
  • March 2019
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • May 2018
  • April 2018
  • February 2018
  • January 2018
  • December 2017
  • September 2017
  • August 2017
  • June 2017
  • April 2017
  • March 2017
  • February 2017
  • December 2016
  • October 2016
  • August 2016
  • July 2016
  • May 2016
  • January 2016
  • December 2015
  • October 2015
  • December 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • September 2013
  • June 2013
  • September 2012
  • July 2012
  • January 2012
  • August 2011
  • January 2011
  • November 2010
  • April 2010
  • February 2009
  • March 2007
  • Privacy Policy
  • Terms and Conditions